[Clinical evaluation and immunomodulatory study of cefodizime].
To investigate the efficacy, safety and immunomodulating activities of cefodizime in immunocompromised patients with infections, we carried out a randomized controlled prospective study of cefodizime vs ceftizoxime in 107 patients. The total effective cure rate and bacterial eradication rate were 87.3%, 61.8% and 89.3% in cefodizime group and 82.7%, 59.6% and 90.6% in ceftizoxime group. Drug tolerance was similar in the two groups, and side effect was mild and transient, mainly gastrointestinal reactions. Cefodizime had effect on both phagocyte and lymphocyte functions: enhancing the phagocytie rate, phagocytic index and bacterial killing activity, increasing the number of CD4+ lymphacyte and the ratio of CD4+/CD8+, stimulating NK cell activity and enhancing expression of IL-2R of active lymphocyte. Meanwhile ceftizoxime had no effect on any of the parameter mentioned above. The result showed that cefodizime is effective and safe in the treatment of LRTI, upper and complicated UTI in immunocompromised patients, as well as possessed immunomodulating activities.